Holstein SA, Atrash S, Mian H, Dimopoulos MA, Schjesvold F, Popat R, Shah N, Gatt ME, Gocke CB, Frenzel L, Touzeau C, Beksac M, Manier S, Magen H, Travis P, Nadeem O, Suryanarayan K, Li C, Li S, Nelson A, Cherepanov D, Parot X, Vogl DT (2025)
A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma
Blood (in press)
DOI 10.1182/blood.2024027873, PubMed 40279508

Gundesen MT, Schjesvold F, Lund T (2025)
Treatment of myeloma bone disease: When, how often, and for how long?
J Bone Oncol, 52, 100680
DOI 10.1016/j.jbo.2025.100680, PubMed 40242221

Richter J, Nooka A, Rodríguez-Otero P, Schjesvold F, Katodritou E, Combe E, Scott M, Cooper L, Sly I, Ballew N, Bitetti J, Boytsov N, Purser M, McNamara S (2025)
Belantamab Mafodotin Plus Proteasome Inhibition Efficacy Versus Comparators in Early Relapsed Myeloma: A Systematic Review and Network Meta-Analysis
Am J Hematol (in press)
DOI 10.1002/ajh.27661, PubMed 40143674